(Reuters) – Data from a late-stage study revealed GSK’s Blenrep significantly reduced disease progression or death risk. This promising result offers hope for multiple myeloma patients.
Seventy-one percent of patients who received Blenrep with dexamethasone and pomalidomide had disease-free survival after a year. The trial included 302 patients with relapsed or difficult-to-treat multiple myeloma.
That compared with progression-free survival (PFS) of 51% of those who were treated with pomalidomide, dexamethasone and bortezomib. Pomalidomide is a generic version of Bristol Myers Squibb’s Pomalyst, while bortezomib is the generic of Takeda Pharmaceuticals’ Velcade.
“The ability to be able to offer a drug like Blenrep potentially that is administered on an outpatient basis, does not require hospitalization, can be available in a community setting and is not restricted by manufacturing challenges, like cell therapies, is really important,” GSK oncology executive Hesham Abdullah said in an interview.
Detailed data from the trial was presented at the American Society of Clinical Oncology meeting in Chicago on Sunday.
Blenrep has had setbacks over the last couple of years, including being pulled from the lucrative U.S. market in 2022 after it failed to show superiority over an existing treatment in a separate late-stage study.
The promising results of GSK’s blood cancer drug trial pave the way for future advancements in cancer care.
Additionally, the findings highlight the importance of personalized treatment approaches in oncology.
Furthermore, ongoing clinical trials and real-world evidence will provide further insights into the long-term efficacy and safety of the blood cancer drug.
read more
image source
